Menu

About Us

Fresenius Kabi at a glance

Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.



In 2016 the company reported sales of €6 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

Key Figures

 
€ in millions 2016 2015 Change
Sales 6,007 5,950 1%
EBITDA¹ 1,479 1,446 2%
EBIT¹ 1,224 1,189 3%
Net Income² 716 669 7%
Employees 34,917 33,195 5%

        

?1 2015 before special items
2 Net income attributable to shareholders of Fresenius Kabi AG; 2015 before special items